{"id":50646,"date":"2022-11-09T09:02:36","date_gmt":"2022-11-09T08:02:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/"},"modified":"2022-11-09T09:02:36","modified_gmt":"2022-11-09T08:02:36","slug":"tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/","title":{"rendered":"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US"},"content":{"rendered":"
\n

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities. The current US clinical trials are run in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA and the Merck-Pfizer-Alliance.\n<\/p>\n

<\/a><\/p>\n

\nTILT Biotherapeutics\u2019 CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients with earlier versions of oncolytic viruses, said, \u201cBoston is at the heart of one of the world\u2019s biggest biotech clusters, and we\u2019re delighted to become part of that vibrant community as we invest in this infrastructure and accelerate towards Phase 2 trials of our innovative armed oncolytic viruses.\u201d\n<\/p>\n

\nTILT Biotherapeutics\u2019 COO, and President of US operations, Aino Kalervo, who is responsible for initiating the US office operations, said \u201cOur newly established US operations will help to drive our US clinical development in this leading global pharmaceutical market, including lining up several new clinical trial centers, building on our work with the Mayo Clinic, and supporting forthcoming IND filings.\u201d\n<\/p>\n

\nJohn Goldfinch, TILT Biotherapeutics\u2019 newly appointed US Clinical Lead, with over a decade\u2019s phase I to IV clinical operations and program management experience at US life sciences companies including Athenex, said, \u201cI\u2019m delighted to join TILT to help advance our US program of phase I and II clinical trials. We believe our approach will deliver better outcomes for cancer patients.\u201d\n<\/p>\n

\nTILT Biotherapeutics LLC\u2019s new office is at the CIC in Boston, Massachusetts which has been a home for great entrepreneurs leading fast-growing companies since 1999. This follows its collaborations with US pharma partners and leading cancer centers.\n<\/p>\n

\nThe heart of TILT\u2019s innovative approach revolves around the use of cancer cell specific oncolytic adenoviruses, armed with cytokines and other molecules to boost the patient\u2019s T-cell immune response to better enable it to find and destroy cancer cells.\n<\/p>\n

\n-Ends-\n<\/p>\n

\nNotes to Editors<\/b>\n<\/p>\n

\nAbout TILT Biotherapeutics<\/b>\n<\/p>\n

\nTILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company\u2019s patented TILT\u00ae<\/sup> technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as immune checkpoint inhibitors, tumor infiltrating lymphocyte (TIL) therapy, and CAR T therapies.\n<\/p>\n

\nTILT\u2019s lead asset, TILT-123, is a 5\/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo<\/i>, and it is currently in Phase I clinical trials.\n<\/p>\n

\nThe company\u2019s pioneering approach has been recognized by industry leaders including with the Merck KGaA and Pfizer Alliance, who are collaborating to investigate TILT-123\u2019s therapeutic effect in combination with the PD-L1 inhibitor, Avelumab (Bavencio\u00ae<\/sup>), in head and neck cancer (NCT05222932). The company has two collaborations with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, investigating TILT-123 in combination with pembrolizumab (KEYTRUDA\u00ae<\/sup>) in ovarian cancer (NCT05271318) and in refractory non-small cell lung cancer. In 2019, TILT established an additional partnership with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China, for the development and commercialization of TILT\u2019s proprietary oncolytic virus TILT-123 in Greater China.\n<\/p>\n

\nBased in Helsinki, Finland, and with an office in Boston, the company was established in 2013 as a spin-out from the University of Helsinki. It has funding from Lifeline Ventures, Finnish Industry Investment (TESI), angel investors, Business Finland, and the European Innovation Council.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contacts<\/b>
TILT Biotherapeutics<\/b>
COO Aino Kalervo
\n
aino@tiltbio.com<\/a>\n<\/p>\n

\nScius Communications<\/b>
Katja Stout
\n
+447789435990
\n
katja@sciuscommunications.com<\/a>\n<\/p>\n

\nDaniel Gooch
\n
+44774787 479
\n
daniel@sciuscommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities. The current US clinical trials are run in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA and the Merck-Pfizer-Alliance. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50646","6":"format-standard","7":"category-industry"},"yoast_head":"\nTILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities. The current US clinical trials are run in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA and the Merck-Pfizer-Alliance. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-09T08:02:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221109005036\/en\/1627613\/21\/TILT_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US\",\"datePublished\":\"2022-11-09T08:02:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/\"},\"wordCount\":632,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005036\\\/en\\\/1627613\\\/21\\\/TILT_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/\",\"name\":\"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005036\\\/en\\\/1627613\\\/21\\\/TILT_logo.jpg\",\"datePublished\":\"2022-11-09T08:02:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005036\\\/en\\\/1627613\\\/21\\\/TILT_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005036\\\/en\\\/1627613\\\/21\\\/TILT_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/","og_locale":"en_US","og_type":"article","og_title":"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US - Pharma Trend","og_description":"HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities. The current US clinical trials are run in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA and the Merck-Pfizer-Alliance. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-09T08:02:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221109005036\/en\/1627613\/21\/TILT_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US","datePublished":"2022-11-09T08:02:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/"},"wordCount":632,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221109005036\/en\/1627613\/21\/TILT_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/","url":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/","name":"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221109005036\/en\/1627613\/21\/TILT_logo.jpg","datePublished":"2022-11-09T08:02:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221109005036\/en\/1627613\/21\/TILT_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221109005036\/en\/1627613\/21\/TILT_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-boston-office-opening-as-it-expands-its-clinical-trials-in-the-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50646"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50646\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}